In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 116-125

  Fernandez, Jeffrey ^a   Hilliard, Jamese J ^a   Abbanat, Darren ^a   Zhang, Wenyan ^a   Melton, John L ^a   Santoro, Colleen M ^a   Flamm, Robert K ^a   Bush, Karen ^a,b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE AMPC; CEFAZOLIN; CEFEPIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CILASTATIN; LINEZOLID; MEROPENEM; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN DEFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HALF-LIFE; IMMUNOCOMPROMISED HOST; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, HAIRLESS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 73849107006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00642-09     Document Type: Article

References (56)

1. Amsler, K. M., T. A. Davies, W. Shang, M. R. Jacobs, and K. Bush. 2008. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 52:3418-3423.
2. Anaya, D. A., and E. P. Dellinger. 2007. Necrotizing soft-tissue infection: diagnosis and management. Clin. Infect. Dis. 44:705-710.
3. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
4. Attassi, K., E. Hershberger, R. Alam, and M. J. Zervos. 2002. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34:695-698.
5. Auckenthaler, R. 2002. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J. Antimicrob. Chemother. 50(Suppl.):13-17.
6. Azoulay-Dupuis, E., J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro. 2004. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:1105-1111.
7. Barg, N. 1998. Comparison of four antibiotics in a murine model of necrotizing cutaneous infections caused by toxigenic Streptococcus pyogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 42:257-260.
8. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
9. Bratzler, D. W., and D. R. Hunt. 2006. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin. Infect. Dis. 43:322-330.
10. Brown, N. P., M. E. Jones, D. C. Draghi, M. K. Aranza, K. Murfitt, C. Thornsberry, and D. Sahm. 2006. Baseline surveillance profiles of ceftobiprole (BPR) activity against Enterobacteriaceae and P. aeruginosa (PA), abstr. E-0112. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
11. Bunce, C., L. Wheeler, G. Reed, J. Musser, and N. Barg. 1992. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 60:2636-2640.
12. Carbon, C. 1999. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J. Antimicrob.Chemother. 44(Suppl. A):31-36.
13. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
14. CLSI. 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Craig, W. A. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3): S233-S237.
16. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
17. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
18. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
19. Davies, T. A., M. G. P. Page, W. Shang, T. Andrew, M. Kania, and K. Bush. 2007. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 2621-2624.
20. Davies, T. A., W. Shang, R. K. Flamm, and K. Bush. 2006. Binding of ceftobiprole and comparators to penicillin-binding proteins in Pseudomonas aeruginosa, abstr. C1-0933. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother.
21. Ena, J., R. W. Dick, R. N. Jones, and R. P. Wenzel. 1993. The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA 269:598-602.
22. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
23. Fernandez, J., J. J. Hilliard, J. L. Melton, D. Abbanat, R. K. Flamm, and K. Bush. 2007. In vivo activity of ceftobiprole in a pseudomonal murine skin infection model, abstr. 437. Abstr. 45th Annu. Meet. Infect. Dis. Soc. Am. (IDSA), San Diego, CA.
24. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, F. C. Tenover, and Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439.
25. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2006. In vitro activity of ceftobiprole tested against a recent collection of North American Pseudomonas aeruginosa (PSA), abstr. E-0115. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC.
26. Fung, H. B., J. Y. Chang, and S. Kuczynski. 2003. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63:1459-1480.
27. Fung, H. B., H. L. Kirschenbaum, and B. O. Ojofeitimi. 2001. Linezolid: an oxazolidinone antimicrobial agent. Clin. Ther. 23:356-391.
28. Gill, C. J., G. K. Abruzzo, A. M. Flattery, A. S. Misura, K. Bartizal, and E. J. Hickey. 2007. In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrob. Agents Chemother. 51:3434-3436.
29. Green, S. L., J. C. Maddox, and E. D. Huttenbach. 2001. Linezolid and reversible myelosuppression. JAMA 285:1291.
30. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broadspectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
31. Hilliard, J. J., J. Fernandez, J. Melton, M. J. Macielag, R. Goldschmidt, K. Bush, and D. Abbanat. 2009. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 53:2028-2033.
32. Hilliard, J. J., W. Zhang, J. Melton, J. Fernandez, R. K. Flamm, and K. Bush. 2006. In vivo anti-pseudomonal acivity of ceftobiprole, abstr. 198. Abstr. 44th Annu. Meet. Infect. Dis. Soc. Am. (IDSA), Toronto, Ontario, Canada.
33. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
34. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
35. Hori, T., M. Nakano, Y. Kimura, and K. Murakami. 2006. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 20:91-96.
36. Jacobs, M. R. 2001. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7:589-596.
37. Knudsen, J. D., K. Fuursted, F. Espersen, and N. Frimodt-Moller. 1997. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob. Agents Chemother. 41:1910-1915.
38. Knudsen, J. D., K. Fuursted, N. Frimodt-Moller, and F. Espersen. 1997. Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model. J. Antimicrob. Chemother. 40:679-686.
39. LaPlante, K. L., S. N. Leonard, D. R. Andes, W. A. Craig, and M. J. Rybak. 2008. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob. Agents Chemother. 52:2156-2162.
40. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.
41. McDonald, L. C. 2006. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin. Infect. Dis. 42(Suppl. 2):S65-S71.
42. McNabb, J. J., and K. Q. Bui. 2002. B-lactam pharmacodynamics, vol. 28. Marcel Dekker, Inc., New York, NY.
43. Milliken, G. A., and D. E. Johnson. 2001. Analysis of messy data, vol. III. Analysis of covariance. CRC Press, Danvers, MA.
44. Noel, G. J., R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
45. Panlilio, A. L., D. H. Culver, R. P. Gaynes, S. Banerjee, T. S. Henderson, J. S. Tolson, and W. J. Martone. 1992. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect. Control Hosp. Epidemiol. 13:582-586.
46. Patel, M. V., N. J. De Souza, S. V. Gupte, M. A. Jafri, S. S. Bhagwat, Y. Chugh, H. F. Khorakiwala, M. R. Jacobs, and P. C. Appelbaum. 2004. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob. Agents Chemother. 48:4754-4761.
47. Queenan, A. M., and K. Bush. 2005. Ceftobiprole: effect on AmpC β-lactamase induction and resistance frequency in gram-negative bacteria. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C1-55, p. 57.
48. Queenan, A. M., W. Shang, M. Kania, M. G. P. Page, and K. Bush. 2007. Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51:3089-3095.
49. Robert, J., R. Bismuth, and V. Jarlier. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506-510.
50. Rybak, M. J., B. M. Lomaestro, J. C. Rotscahfer, R. C. Moellering, W. A. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327.
51. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340:493-501.
52. Stevens, D. L., A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. C. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, J. C. Wade, and Infectious Diseases Society of America. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406. (Erratum, 41:1830.)
53. Stokes, M., C. S. Davis, and G. G. Koch. 1995. Categorical data analysis using the SAS system. SAS Institute, Inc., Cary, NC.
54. Tawara, S., S. Matsumoto, T. Kamimura, and S. Goto. 1992. Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics. Antimicrob. Agents Chemother. 36:17-24.
55. Vaudaux, P., A. Gjinovci, M. Bento, D. Li, J. Schrenzel, and D. P. Lew. 2005. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3789-3793.
56. Zuluaga, A. F., B. E. Salazar, C. A. Rodriguez, A. X. Zapata, M. Agudelo, and O. Vesga. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis. 6:55.